#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Neurodevelopmental disorder Henoch-Schonlein purpura Small cell lung cancer extensive stage Cutaneous T-cell lymphoma Congenital myopathy Enteritis Rosai-Dorfman syndrome Cytomegalovirus infection Adenomatous polyposis coli Small cell lung cancer limited stage Epileptic encephalopathy Glomerulonephritis membranoproliferative Pouchitis Bronchiolitis Congenital growth hormone deficiency More trials…

    Learn about Rare Diseases

    Marginal zone lymphoma – Diagnostics Choroid melanoma Angiosarcoma recurrent – Trials in Disease Idiopathic inflammatory myopathy – Trials in Disease Familial haemophagocytic lymphohistiocytosis Methylmalonic acidaemia – Trials in Disease SAPHO syndrome – Basic Information Alport’s syndrome Fabry’s disease – Trials in Disease Advanced systemic mastocytosis – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Ltx-315 SODIUM SULFIDE NONAHYDRATE Cefepime Gandotinib Zilovertamab Vedotin ANHYDROUS CALCIUM FOLINATE ANTI-GD2-800CW Marstacimab Deferiprone Cagrilintide Rituximab Magnesium Oxybate RO7268489 Liquid Paraffin Arbaclofen Floxuridine Darunavir Dabrafenib Amcenestrant Ozanimod Hydrochloride More therapies…

    Learn about Your Condition

    Atopic keratoconjunctivitis Implantation complication Complicated appendicitis Optic ischaemic neuropathy Acute promyelocytic leukaemia Duchenne muscular dystrophy Benign renal neoplasm Stevens-Johnson syndrome Retinal vein occlusion Colonoscopy Venous thrombosis limb Hypertrophic cardiomyopathy Thalassaemia beta Systemic sclerosis pulmonary Acute hepatic failure More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Duchenne muscular dystrophy

  • Long‑Term Safety and Efficacy Study of ENTR‑601‑45 and ENTR‑601‑44 in Participants with Duchenne Muscular Dystrophy

    Recruiting

    2 1 1
    Belgium Italy The Netherlands Spain

  • Duchenne Muscular Dystrophy in Patients with Gene Mutations Amenable to Exon 44 Skipping Treated with Delpacibart Zotadirsen

    Recruiting

    3 1
    Investigated Diseases:
    • Duchenne muscular dystrophy
    Belgium France Germany Italy The Netherlands Poland +1

  • A study to evaluate the long-term safety and effectiveness of BMN 351 in patients with Duchenne muscular dystrophy amenable to exon 51 skipping.

    Recruiting

    2 1 1
    Italy The Netherlands Spain

  • Study of SAT-3247 Compared to Placebo for Patients with Duchenne Muscular Dystrophy Who Can Walk

    Recruiting

    2 1
    Investigated Diseases:
    • Duchenne muscular dystrophy
    Investigated Drugs:
    • SAT-3247 OXALATE
    Belgium Poland Spain

  • Study of ENTR-601-45 Safety and Effectiveness in Patients with Duchenne Muscular Dystrophy Who Can Skip Exon 45

    Recruiting

    2 1 1
    Investigated Diseases:
    • Duchenne muscular dystrophy
    Investigated Drugs:
    • Sodium Chloride
    Belgium France Italy The Netherlands Poland Spain

  • Study of ENTR-601-44 in Children with Duchenne Muscular Dystrophy Who Are Eligible for Exon 44 Skipping Treatment

    Recruiting

    1 1 1
    Investigated Diseases:
    • Duchenne muscular dystrophy
    Investigated Drugs:
    • Sodium Chloride
    Belgium Italy Spain
1 2 3 … 5
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!